{
    "SPADE_N_13944": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13944",
            "Peptide Name": "Dermaseptin-SS1 (SS1, XXA, UCLL1c; BBL; BBMm; natural AMPs; frog, amphibians, animals)",
            "Source": "Skin Secretion, Brown-belly leaf frog,Phyllomedusa Tarsius, South America",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "ALWKSILKNAGKAALNEINQIV",
            "Sequence Length": 23,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "anti-sepsis",
                "Anticancer"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 2394.81,
            "PI": 9.7,
            "Hydrophobicity": 0.23,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Ma X, Chen Y, Shu A, Jiang Y, Chen X, Ma C, Zhou M, Wang T, Chen T, Shaw C, Wang L. 2023",
                    "Reference": "Molecules. 2023 Sep 11;28(18):6558. doi: 10.3390/molecules28186558.Pub-Med.",
                    "Title": "A Novel Antimicrobial Peptide, Dermaseptin-SS1, with Anti-Proliferative Activity, Isolated from the Skin Secretion of Phyllomedusa tarsius"
                }
            ],
            "Frequent Amino Acids": "AIK",
            "Absent Amino Acids": "CDFHMOPRTUY",
            "Basic Residues": 3,
            "Acidic Residues": 1,
            "Hydrophobic Residues": 12,
            "Polar Residues": 13,
            "Positive Residues": 3,
            "Negative Residues": 1,
            "Net Charge": 2,
            "Comments": "Sequence analysis: APD analysis reveals this sequence is most similar (95.65%) toDermaseptin-PS3A: 17%; I=L=N=K: 13%. GRAVY: 0.065; Mol W: 2522.967; Mol formula: C114H196N29O32; Mol Ex coeff: 5550.Activity: active against S. aureus ATCC CRM 6538 (MIC 8 uM), MRSA NCTC 12493 (MIC > 128 uM), E.faecalis NCTC 12697 (MIC > 128 uM),  E. coli ATCC CRM 8739, resistant ATCC BAA 2340, ATCC BAA 2469, ATCC BAA 2471, or NCTC 13846 (MIC 2-8 uM), K. pneumoniae ATCC 43816 (MIC 16 uM), P. aeruginosa ATCC CRM 9027 (MIC 32 uM), A. baumannii ATCC BAA 747 (MIC 16 uM), and C.albicans ATCC CRM 10231 (MIC >128 uM).Antimicrobial robustness: salt-insensitive; NaCl-insensitive:S. aureus (150 mM); NaCl-insensitive:E. coli (150 mM); KCl-insensitive:S. aureus (5 mM); KCl-insensitive:E. coli (5 mM); MgCl2-insensitive:S. aureus (1.5 mM); MgCl2-insensitive:E. coli (1.5 mM); CaCl2-insensitive:S. aureus (2.5 mM); CaCl2-sensitive:E. coli (2.5 mM); FeCl3-insensitive:S. aureus (4 uM); FeCl3-insensitive:E. coli (4 uM);  NH4Cl-insensitive:S. aureus (6 uM); NH4Cl-insensitive:E. coli (6 uM).Toxicity: 4% horse RBC, HC50 256 uM. Antiproliferative Activity to human lung cancer cell lines H838 and H460: IC50 7.7 and 1.3 uM. Cf: normal HaCaT: IC50: 61.3 uM.Structure: helical in 50% TFE.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_24928",
                    "Similarity": 1.0,
                    "Sequence": "ALWKSILKNAGKALNEINQIVQ"
                },
                {
                    "SPADE_ID": "SPADE_UN_24929",
                    "Similarity": 1.0,
                    "Sequence": "ALWKSILKNAGKAALNEINQIVQ"
                },
                {
                    "SPADE_ID": "SPADE_N_01516",
                    "Similarity": 0.9545454545454546,
                    "Sequence": "ALWKDILKNAGKAALNEINQIVQ"
                }
            ]
        }
    }
}